You Are Here: > Mullen, Douglas

Mullen, Douglas

Douglas Mullen

Education

Bachelor of Science in Engineering
Duke University, 2005

Doctor of Philosophy

University of Michigan, 2010

    About This Team Member

    Douglas Mullen received a Bachelor's of Science in Engineering from Duke University in 2005. At Duke he was a Pratt Undergraduate Research Fellow and a member of the Center for Biologically Inspired Materials and Material Systems. He began his graduate career in the Macromolecular Science and Engineering Program at the University of Michigan in 2005 and became a member of the Banaszak Holl research group and the Michigan Nanotechnology Institute for Medicine and Biological Sciences. In 2007 Doug received a Master's of Science in Engineering from the University of Michigan's Program in Macromolecular Science and Engineering and in 2009 he completed the MBA Essentials and Entrepreneurship Program at Michigan's Ross School of Business. He completed the Doctoral Program in the Macromolecular Science and Engineering Program in 2010.   His thesis work involved the development of targeted chemotherapeutic agents. He received several awards including the Raymond C. Gaugler Award in Materials Science and Engineering at Duke, the Rackham Regents Fellowship at the University of Michigan, an award for Excellence in Graduate Polymer Research from the American Chemical Society, and the National Starch and Chemical Award from the Macromolecular Science and Engineering Program at the University of Michigan.  A review article describing much of Doug's graduate research was published as the cover article in Account of Chemical Research.

    Doug spent a year as a Medical Innovation fellow at the University of Michigan's medical school and then worked at MNIMBS as our technology translation specialist.

    Doug is currently Senior Analyst at Fletcher Spaght, Inc, a venture capital fund investing in emerging growth high technology and healthcare companies in Boston, Massachusetts.  This firm provides strategy and financing assistance to new ventures, including start-up companies, risk capital investors and emerging technologies/growth enterprises within larger organizations.

     

     

    Publications

    Best Practices for Purification and Characterization of PAMAM Dendrimer

    D. G. Mullen, A. Desai, M. A. Van Dongen, M. Barash, J. R. Baker, M. M. Banaszak Holl
    Macromolecules
    2012
    45
    5316-5320

    Dendrimer-Based Nanoparticle Therapies: Can Uniform Multifunctional Therapeutics Be Made with Current Chemical Approaches?

    D. G. Mullen, D. Q. McNerny, M. M. Banaszak Holl, J. R. Baker
    2012

    Acetonitrile Shortage: Use of isopropanol as an alternative elution system for ultrahigh performance liquid chromatograph

    A. M. Desai, M. Andreae, D. G. Mullen, M. M. Banaszak Holl, J. R. Baker
    Analytical Methods
    2011
    3,
    56-58.

    Heterogeneous ligand-nanoparticle distributions: a major obstacle to scientific understanding and commercial translation

    D. G. Mullen, M. M. Banaszak Holl
    Accounts of Chemical Research
    2011
    44,
    1135-1252
    Design, Synthesis, and Biological Functionality of a Dendrimer-based Modular Drug Delivery Platform
    . D. Mullen, D. McNerny, A. Desai, X.-M. Chen, S. DiMaggio, A. Kotlyar, Y. Zhong, S. Qin, C. V. Kelly, T. Thomas, I. Majoros, B. G. Orr, J. R. Baker, M. M. Banaszak Holl
    Bioconjugate Chemistry
    2011
    22,
    679-689

    A Quantitative Assessment of Nanoparticle-Ligand Distributions: Implications for Targeted Drug and Imaging Delivery in Dendrimer Conjugates

    D. G. Mullen, M. Fang, A. M. Desai, J. R. Baker, B. G. Orr, and M. M Banaszak Holl
    ACS Nano
    2010,
    4,
    657-670.

    Effect of Mass Transport in the Synthesis of Partially Acetylated Dendrimer:  Implications for Functional Ligand-Nanoparticle Interactions

    D. G Mullen, E. L. Borgmeier, M. Fang, D. Q. McNerny, A. Desai, J. R. Baker, B. G. Orr, M. M. Banaszak Holl
    Macromolecules
    2010,
    43,
    6577-6587.

    Isolation and Characterization of Dendrimers with Precise Numbers of Functional Groups

    D. G Mullen, E. L. Borgmeier, A. Desai, M. A. Van Dongen, M. Barash, X.-M. Chen, J. R. Baker, B. G. Orr, M. M. Banaszak Holl
    Chemistry a European Journal
    2010,
    10,
    10675-10678.

    Polycation-Induced Cell Membrane Permeability Does Not Enhance Cellular Uptake or Expression Efficiency of Delivered DNA

    L. Prevette, D. Mullen, M. M. Banaszak Holl
    Molecular Pharmaceutics
    2010,
    7,
    870-883.

    Solid State NMR Reveals the Hydrophobic-Core Location of Poly(amidoamine) Dendrimers in Biomembranes

    P. Smith, J. Brender, U. Durr, J. Xu, D. Mullen, M. M. Banaszak Holl, A Ramamoorthy
    J. Am. Chem. Soc.
    2010,
    132,
    8087-8097.

    The Mechanism of Polyplexes Internalization into Cells: Testing the GM1/Caveolin-1-Mediated Lipid Raft Mediated Endocytosis Pathway

    R. Qi, D. Mullen, J. R. Baker, M. M. Banaszak Holl
    Molecular Pharmaceutics
    2010,
    7,
    267-279.
    Origin of broad polydispersion in functionalized dendrimers and its effects on cancer-cell binding affinity
    J. N. Waddell, D. G. Mullen, B. G. Orr, M. M. Banaszak Holl, L. M. Sander
    Physical Review E
    2010,
    82,
    036108

    Cationic Nanoparticles Induce Nanoscale Disruption in Living Cell Plasma Membranes

    J. Chen, J. A. Hessler, K. Putchakayala, B. K. Panama, D. P. Khan, S. Hong, D. G. Mullen, S. C. DiMaggio, A. Som, G. N. Tew, A. N. Lopatin, J. R. Baker, M. M. Banaszak Holl, B. G. Orr
    Journal of Physical Chemistry B
    2009,
    113,
    11179-11185

    Cationic Poly(amidoamine) Dendrimer Induces Lysosomal Apoptotic Pathway at Therapeutically Relevant Concentrations

    T. P. Thomas, I. Majoros, A. Kotlyar, D. Mullen, M. M. Banaszak Holl and J. R. Baker
    Biomacromolecules
    2009,
    10,
    3207–3214.

    RGD Dendron Bodies: Synthetic Avidity Agents with Defined and Potentially Interchangeable Effector Sites That Can Substitute for Antibodies

    D. Q. McNerny, J. F. Kukowska-Latallo, D. G. Mullen, J. M. Wallace, A. M.Desai, R. Shukla, B. Huang, M. M. Banaszak Holl, J. R. Baker
    Bioconjugate Chemistry
    2009,
    20,
    1853-1859.

    The Role of Ganglioside GM1 in Cellular Internalization Mechanisms of Poly(amidoamine) Dendrimers

    S. Hong, R. Rattan, I. Majoros, D. G. Mullen, J. L. Peters, X. Shi, A. U. Bielinska, L. Blanco, B. G. Orr. J. R. Baker, M. M. Banaszak Holl
    Bioconjugate Chemistry
    2009,
    20,
    1503-1513.

    Stoichiometry and Structure of Poly(amidoamine) Dendrimer-Lipid Complexes

    C. V. Kelly, M. G. Liroff, L. D. Triplett, P. R. Leroueil, D. G. Mullen, J. M. Wallace, S. Meschinchi, J. R. Baker, B. G. Orr, M. M. Banaszak Holl
    ACS Nano
    2009
    3,
    1886-1896.

    The Implications of Stochastic Synthesis for the Conjugation of Functional Groups to Nanoparticles

    D. G. Mullen, A. M. Desai, J. N. Waddell, X.-M. Chen, C. V. Kelly, D. Q. McNerny, I. J. Majoros, J. R. Baker, L. M. Sander, B. G. Orr, and M. M. Banaszak Holl
    Bioconjugate Chemistry
    2008,
    19,
    1748-1752.

    Interaction of Poly(amidoamine) Dendrimers with Survanta Lung Surfactant:  The Importance of Lipid Domains

    B. Erickson, S. DiMaggio, D. G. Mullen, C. V. Kelly, P. R. Leroueil, S. A. Berry, J. R. Baker, Jr., B. G. Orr, M. M. Banaszak Holl
    Langmuir
    2008
    24
    11003-11008